| Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products M Ibrahim, E Ramadan, NE Elsadek, SE Emam, T Shimizu, H Ando, ... Journal of Controlled Release 351, 215-230, 2022 | 158 | 2022 |
| Cancer cell-type tropism is one of crucial determinants for the efficient systemic delivery of cancer cell-derived exosomes to tumor tissues SE Emam, ASA Lila, NE Elsadek, H Ando, T Shimizu, K Okuhira, Y Ishima, ... European Journal of Pharmaceutics and Biopharmaceutics 145, 27-34, 2019 | 58 | 2019 |
| Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice SE Emam, NE Elsadek, ASA Lila, H Takata, Y Kawaguchi, T Shimizu, ... Journal of Controlled Release 334, 327-334, 2021 | 44 | 2021 |
| Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of … MM El Sayed, H Takata, T Shimizu, Y Kawaguchi, ASA Lila, NE Elsadek, ... Journal of Controlled Release 323, 102-109, 2020 | 40 | 2020 |
| Electrospun nanofibers revisited: an update on the emerging applications in nanomedicine NE Elsadek, A Nagah, TM Ibrahim, H Chopra, GA Ghonaim, SE Emam, ... Materials 15 (5), 1934, 2022 | 33 | 2022 |
| Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice NE Elsadek, ASA Lila, SE Emam, T Shimizu, H Takata, H Ando, Y Ishima, ... European Journal of Pharmaceutics and Biopharmaceutics 152, 56-62, 2020 | 23 | 2020 |
| Immunological responses to PEGylated proteins: anti-PEG antibodies NE Elsadek, ASA Lila, T Ishida Polymer-Protein Conjugates, 103-123, 2020 | 22 | 2020 |
| Impact of pre-existing or induced anti-PEG IgM on the pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in mice NE Elsadek, E Hondo, T Shimizu, H Takata, AS Abu Lila, SE Emam, ... Molecular Pharmaceutics 17 (8), 2964-2970, 2020 | 19 | 2020 |
| Pegfilgrastim (PEG-G-CSF) Induces anti-polyethylene glycol (PEG) IgM via a T cell-dependent mechanism NE Elsadek, SE Emam, ASA Lila, T Shimizu, H Ando, Y Ishima, T Ishida Biological and Pharmaceutical Bulletin 43 (9), 1393-1397, 2020 | 15 | 2020 |
| Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route H Takata, T Shimizu, R Yamade, NE Elsadek, SE Emam, H Ando, ... Journal of Controlled Release 360, 285-292, 2023 | 10 | 2023 |
| Nucleic acids delivered by PEGylated cationic liposomes in systemic lupus erythematosus-prone mice: a possible exacerbation of lupus nephritis in the presence of pre-existing … H Takata, T Shimizu, Y Kawaguchi, H Ueda, NE Elsadek, H Ando, ... International Journal of Pharmaceutics 601, 120529, 2021 | 9 | 2021 |
| Complement activation-related pseudo allergy of PEGylated products: Safety aspects, models, the role of anti-PEG antibodies, and ways to overcome M Mohamed, N Elsadek, S Emam, U Farghaly, H Sarhan Journal of advanced Biomedical and Pharmaceutical Sciences 5 (2), 79-87, 2022 | 5 | 2022 |
| Incorporating gangliosides into PEGylated cationic liposomes that complexed DNA attenuates anti-PEG antibody production but not anti-DNA antibody production in mice MR Qelliny, T Shimizu, NE Elsadek, SE Emam, H Takata, ZMA Fathalla, ... Molecular Pharmaceutics 18 (6), 2406-2415, 2021 | 5 | 2021 |
| The Post-insertion Method for the Preparation of PEGylated Liposomes SE Emam, NE Elsadek, T Shimizu, T Ishida Liposomes: Methods and Protocols, 159-172, 2023 | 2 | 2023 |
| Using bio-layer interferometry to evaluate anti-PEG antibody-mediated complement activation M Mostafa, NE Elsadek, SE Emam, H Ando, T Shimizu, H Abdelkader, ... Biological and Pharmaceutical Bulletin 45 (1), 129-135, 2022 | 2 | 2022 |
| SARS-CoV-2 vaccines from A to Z: A review of the current challenges JM Albalaty, FH Forsan, SS Awad, EN Elsadek, AAG Rahman, M Badawy, ... GLOBAL NEST JOURNAL 25 (4), 148-171, 2023 | | 2023 |
